🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Chinese Hamster Ovary, or CHO cells, make roughly 70 percent of all F.D.A. approved biologics sold on the market. This includes bestsellers like Humira®, used to treat Crohn’s and rheumatoid arthritis, and Keytruda®, a cancer therapy. Despite their ubiquity in the pharmaceutical

Still trying to comprehend how the FDA rejected Replimune RP1 drug for #melanoma. No safety issues. Cited mixed inclusion criteria (different treatment regimens), inability to tell if RP1 contributed to response rate post-PD1 failure. cancernetwork.com/view/fda-gives… see thread below:

2. Thus, saying that RP1 did not contribute to response, or that its contribution was unclear, is really flat out FALSE and shows an unfortunate lack of insight. The exact quote: "its specific contribution to the observed ORR cannot be determined". If nivo alone in post-PD1

Abscopal effect. cc Anil Makam

RFK Jr sounds learned and knowledgeable to the uninformed He sounds like a fraudulent quack to experts The classic con man

The modern cardiovascular drug development landscape has been largely shaped by human genetic studies. Emerging IL-6 targeting therapies are a landmark example. In this Circulation: Genomic and Precision Medicine paper with the Tourmaline Bio team (developing an anti-IL6 antibody for atherosclerotic

Cc Michael Torres CrossBridge in the review!

FDA’s top cancer drug regulator played key role in rejection of Replimune $REPL therapy, officials say statnews.com/2025/08/04/rep…

We scooped the Pazdur news on Friday…btw

Jing Liang 🇺🇦 Honestly, reading the article, Pazdur sounds a bit like a luddite. He doesn't believe abscopal effect?

This is a brilliant market cap chart Source Visual Capitalist

Each year, we highlight companies that received sizeable early-stage funding in the previous year. SeaportTx is modifying central nervous system drugs for delivery through the lymphatic system, bypassing first-pass liver metabolism go.nature.com/45fyNQy

Wow, very interesting how $XOMA pivoted to a royalty corp.

AbbVie flashes eye-opening results for Rinvoq in alopecia areata fiercepharma.com/pharma/abbvie-…

FDA: your drug is promising but we can't approve it, because a senior advisor had a last-minute question and there wasn't enough time for further discussion so my director made a final call before he resigned. but tomorrow he will return. Good to sync on this? Replimune: ...

We have dramatically increased splice switching *and* RNase-H ASO activity by conjugating a nuclear importer! Published in J. Am. Chem. Soc. Led by Disha Kashyap, with Tom Milne NATA - Nucleic Acid Therapy Accelerator Chemistry in Cells Oxford Chemistry UCL Chemistry pubs.acs.org/doi/10.1021/ja…

Is it that bad in Boston??